Coste de la terapia antirretroviral y del año de vida ajustado por calidad (AVAC) en pacientes VIH+

• Autores: A. Alberdi, C. Quintana, José Antonio Martín Conde, L. Álvarez Rubio
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 5, Nº. 6, 2003, págs. 337-344
• Idioma: español
• Títulos paralelos:
  • Costs of antiretroviral therapy and the quality adjusted life year (QALY) in HIV-u infected patients
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objectives: To evaluate the impact of the antiretroviral treatment on the HIV+ patient's quality of life, and to determine and compare the cost per year-of-life adjusted per quality in naïve and non-naïve patients. Patients and methods: To a sample of 60 patients, 30 in each arm, it was administered the EUROQOL-5D survey, determining also the hospital activity generated by these patients. The calculation of costs took place from an institutional perspective, by considering only the direct costs. Results: The hospital activity generated by the two groups of patients did not show any statistically significant differences, while the treatment cost did show them (6,165.09 vs. 8,210.63 ). No differences were found in regards to the quality of life variables between the two groups of patients. The social fee for these patients showed a similar value to the one found in other chronic patients. Conclusions: Delaying the transition from a naïve to a non-naïve patient needs to be a goal to be pursued in order to improve the quality of life of the HIV+ patient, the use of resources and the dependence of the patient from the hospital environment